skip to Main Content

Interview with Piero Di Lorenzo «The Oxford vaccine has an efficacy of 90%»

Il Messaggero

Interview with Piero Di Lorenzo «The Oxford vaccine has an efficacy of 90%»
photo source: Il Messaggero

Piero Di Lorenzo is President and CEO of IRBM, the Italian company, located in Pomezia (Rome), currently engaged in the development of the vaccine together with the Jenner Institute of Oxford. The vaccine will then be produced and marketed by AstraZeneca, and Italy has already purchased 70 million doses. Phase III clinical trials will soon be completed, while the results from phase I trials have shown that the “Oxford-IRBM-AstraZeneca” vaccine has an efficacy rate of 90%. It can be stored at a temperature of -4°/-8° C, but Di Lorenzo stresses: «No comparisons with other vaccines: the world and Italy will need several effective products»

Article by Mauro Evangelisti published on Il Messaggero12/11/2020

Download pdf

Back To Top